REMD Biotherapeutics

Executive Summary

REMD Biotherapeutics is a private, clinical-stage biopharmaceutical company founded by former Amgen scientists, with R&D operations in the US and China. The company specializes in developing innovative antibody-based therapeutics for metabolic diseases, cancer, and other serious conditions. Its lead program, REMD-477 (Volagidemab), is a fully human glucagon receptor antagonist antibody currently in Phase 2 development for indications including type 1 diabetes and nonalcoholic steatohepatitis (NASH). REMD-477 aims to reduce hepatic glucose production and improve glycemic control, addressing significant unmet needs in metabolic disorders. The company's pipeline also includes preclinical programs targeting oncology and other areas, leveraging its proprietary antibody discovery platform. REMD-477 has shown promising safety and efficacy signals in early-phase trials, and ongoing Phase 2 studies are evaluating its potential as a once-weekly injectable therapy. Positive data could position the drug as a first-in-class treatment for hyperglycemia in diabetes and potentially for fibrosis in NASH. As a private company, REMD's catalysts are tied to clinical milestones and potential strategic partnerships or financing events. While the lack of public disclosures limits visibility, the science is compelling and supported by strong mechanistic rationale. The company's near-term outlook hinges on Phase 2 readouts, which could drive significant value inflection.

Upcoming Catalysts (preview)

• H2 2026Phase 2 data readout for REMD-477 in type 1 diabetes35% success
• 2027Phase 2 data readout for REMD-477 in NASH25% success
• 2026Potential partnership or licensing deal for REMD-47720% success